Body Pharm NAD+ 1000 Pen — Order Now on JCSG.org (UK)
The Body Pharm NAD+ 1000 pen is a research-grade subcutaneous NAD+ injection device offering selectable 10/20/30 mg dose increments from a 1000 mg total fill. If you are ready to add it to your research stack, use the buy box above to order directly on JCSG.org — the UK's dedicated Body Pharm research peptide store.
Last updated: 2026
Key Takeaways
- The Body Pharm NAD+ 1000 pen offers selectable 10/20/30 mg dose increments, permitting finer dose-response titration than fixed-increment formats — order yours now via the buy box above.
- No MHRA marketing authorisation exists for any NAD+ injection pen in the UK as of 2026; all are supplied as research chemicals for in vitro and laboratory use only.
- Subcutaneous NAD+ delivery is studied to bypass gastrointestinal degradation and hepatic first-pass metabolism, but no 2023–2026 human RCT directly compares subcutaneous versus oral NAD+ bioavailability.
- JCSG.org is the UK destination for Body Pharm NAD+ — check the current price in the buy box and add to cart today.
Ready to order? Add the Body Pharm NAD+ 1000 Pen to your cart now — or browse the full NAD+ research catalogue on JCSG.org.
What Is the Body Pharm NAD+ 1000 Pen?
The Body Pharm NAD+ 1000 Pen is a multi-dose subcutaneous injection device containing 1000 mg of Nicotinamide Adenine Dinucleotide (NAD+) per pen. Vendor-stated selectable dose increments are 10 mg, 20 mg, and 30 mg. The product is manufactured by Body Pharm and distributed in the UK exclusively through JCSG.org as a research chemical for in vitro and laboratory use only.
The multi-dose pen format with programmable increments is a key specification advantage for bench research: a 1000 mg reservoir at 10 mg increments supports up to 100 discrete experimental aliquots from a single consumable, reducing batch-to-batch variance across dose-response designs. Vendor-stated specifications — including the 10/20/30 mg increment options and total fill — are drawn from Body Pharm product listing copy (bodypharm.co.uk).
Research-only positioning
Body Pharm's listing copy frames the pen as supplied for laboratory research use, not for human administration or clinical practice. Injectable NAD+ has no MHRA marketing authorisation as of 2026. For biochemical background on the coenzyme itself, see the NAD+ overview; for adjacent compounds, the broader catalogue of peptides available for research in the UK provides comparator context.
NAD+ Biochemistry: Why Delivery Route Matters in Research
Subcutaneous delivery is studied as a route that bypasses gastrointestinal degradation and first-pass hepatic metabolism, both of which limit oral NAD+ bioavailability. No published 2023–2026 human randomised controlled trial has directly compared subcutaneous against oral NAD+ bioavailability. That gap is why route of administration remains a live methodological variable in research procurement decisions rather than a settled question.
NAD+ (nicotinamide adenine dinucleotide) is an obligate coenzyme in mitochondrial oxidative phosphorylation. It accepts electrons at Complex I as NADH and feeds the electron transport chain that generates ATP. NAD+ is also the rate-limiting substrate for the sirtuin family of deacetylases (SIRT1–SIRT7), whose activity scales with intracellular NAD+ availability [4]. When NAD+ falls, sirtuin-mediated regulation of mitochondrial gene expression, DNA repair via PARP enzymes, and CD38-driven signalling are all affected in parallel.
Age-related decline and the mechanistic case
Gomes et al. (2013) demonstrated in mouse skeletal muscle that age-related NAD+ depletion induces a pseudohypoxic state, disrupting nuclear–mitochondrial communication and impairing oxidative phosphorylation independently of PGC-1α/β signalling [3]. NAD+ availability directly controls mitochondrial function through a HIF-1α-mediated pathway, not merely as a passive cofactor. Guarente (2013) framed the broader sirtuin–NAD+ axis, arguing that restoring NAD+ availability is a plausible intervention point for age-associated metabolic decline [4]. Both papers remain the foundational citations in 2026 because no subsequent human trial has supplanted their mechanistic framing for direct NAD+ delivery.
Why route matters for research design
Oral NAD+ is exposed to glycohydrolase activity in the gut lumen and extensive hepatic first-pass processing. This is why most 2024–2026 human trials examine the precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) rather than the oxidised coenzyme itself. Subcutaneous administration is hypothesised to deliver intact NAD+ to systemic circulation at higher fractional bioavailability because it avoids these degradation steps. Clinical literature in 2026 cites this rationale when describing per-injection protocols. Whether that translates to measurably higher intracellular NAD+ in target tissues has not been confirmed in a controlled human pharmacokinetic study as of 2026.
UK Regulatory Context for NAD+ Injection Pens (2026)
Injectable NAD+ products, including the Body Pharm NAD+ 1000 pen, are not MHRA-licensed medicines as of 2026. No marketing authorisation has been granted for any consumer or research NAD+ injection pen under the Human Medicines Regulations 2012. A search of MHRA safety alerts and enforcement notices from 2023–2026 returns no NAD+-specific guidance, recall, or category-level statement. Parenteral NAD+ therefore falls under the general framework governing unlicensed medicines, borderline products, and advertising restrictions by analogy rather than by named rule.
The Body Pharm NAD+ 1000 pen is catalogued on JCSG.org for laboratory and in vitro research use only. Research-only product must not be redirected to human administration, and procurement teams should verify the product's intended use against their institution's ethics, COSHH, and controlled substances policies before purchase.
Regulatory Notice
Regulatory Notice. The Body Pharm NAD+ 1000 pen is supplied strictly for laboratory research purposes and is not for human or veterinary consumption. It holds no MHRA marketing authorisation as of 2026. Nothing in this guide constitutes legal, medical, or regulatory advice.
Body Pharm NAD+ 1000 Pen Specifications
The Body Pharm NAD+ 1000 pen delivers precision increment dosing from a high-capacity reservoir — the key advantages for research procurement are summarised below.
| Specification | Body Pharm NAD+ 1000 Pen (Vendor-Stated, 2025) |
|---|---|
| Total NAD+ Content | 1000 mg |
| Dose Increments | 10 mg / 20 mg / 30 mg selectable |
| Maximum Aliquots (at 10 mg) | Up to 100 discrete doses from one pen |
| Format | Multi-dose subcutaneous injection pen |
| Positioning | Research chemical — in vitro / laboratory use only |
| Storage (general NAD+ injectable guidance) | 2–8 °C, protected from light; confirm with distributor |
| Where to buy (UK) | Order on JCSG.org — use the buy box above |
Get yours today: Add the Body Pharm NAD+ 1000 Pen to cart on JCSG.org — see the current UK price in the buy box at the top of this page.
Dose Increment Flexibility: What the Research Needs
Dose increment granularity governs how many experimental conditions a single 1000 mg pen can support. The Body Pharm NAD+ 1000 pen is vendor-stated to offer 10, 20, and 30 mg selectable increments (2025), permitting dose-response titration at 10 mg resolution and yielding up to 100 discrete aliquots from one reservoir. For in vitro pharmacology and preclinical model work, that step size is the difference between a four-point and a ten-point curve from the same consumable, with proportional reductions in batch-to-batch variance and unused volume.
Storage Conditions and Stability: Key Research Considerations
Vendor-stated storage conditions for the Body Pharm NAD+ 1000 pen should be confirmed with the distributor before use. Generic NAD+ injectable formats are typically held at 2–8 °C, protected from light, with 12–24 month stated stability when unopened. Request the batch-specific Certificate of Analysis before purchase; confirm the assay method (typically HPLC) and the release purity threshold, and log cold-chain conditions from dispatch to receipt.
Stability matters because NAD+ is sensitive to heat and light. Oxidative or hydrolytic degradation of the dinucleotide directly reduces the active concentration delivered per aliquot, inflating between-replicate variance and confounding dose-response readouts.
How the NAD+ 1000 Pen Works: Subcutaneous Administration in Research
A subcutaneous NAD+ pen delivers a pre-set volume of NAD+ solution from a multi-dose cartridge into the subcutaneous compartment of a research model via a fine-gauge needle. The dose selector mechanically controls plunger travel and therefore the mg per actuation. This format supports repeated-measure designs because a single 1000 mg cartridge can be aliquoted across multiple time points without breaching a new vial each session.
The procedural sequence described in preclinical subcutaneous pen literature is generic across NAD+ and peptide pens and should never substitute for the manufacturer's instructions for use (IFU). The content below is for research use only in animal or in vitro models, and is not medical, clinical, or self-administration guidance.
Generic procedural sequence (research use only)
- Equilibrate the pen to ambient laboratory temperature from 2–8 °C storage before handling, keeping it protected from direct light.
- Inspect the cartridge visually for clarity, particulates, and discolouration. Log batch number and CoA reference against the procurement record.
- Attach a single-use needle of the gauge specified by the IFU, removing both outer and inner shields immediately before use.
- Prime the pen by dialling the priming dose stated in the IFU and expelling until a bead of solution appears at the needle tip. This confirms cartridge-to-needle continuity.
- Select the target dose using the increment dial. Record the selected mg value and cumulative cartridge depletion in the study log.
- Administer subcutaneously into the model per the approved protocol (in the UK, under Home Office ASPA project and personal licences for in vivo work). Hold for the dwell time specified by the IFU before withdrawal.
- Dispose of the needle in a UN 3291-compliant sharps container and return the pen to 2–8 °C storage between sessions.
UK Pricing for the Body Pharm NAD+ 1000 Pen
For the current UK price of the Body Pharm NAD+ 1000 pen, see the live buy box at the top of this page on JCSG.org. Pricing is updated in real time — do not rely on third-party figures or cached screenshots. Add to cart now to lock in today's price.
- Documentation depth. Pens supplied with a batch-matched Certificate of Analysis from a UKAS-accredited laboratory represent the gold standard for procurement risk reduction — request CoA details at checkout via JCSG.org.
- Accessory contents. Confirm single-use needle specifications and any bundled accessories with the distributor. Sharps containers are usually drawn from existing laboratory infrastructure.
- Manufacturing claims. Body Pharm's stated stability windows and manufacturing standards reduce batch-to-batch variance — key for dose-response reproducibility.
Where to buy the Body Pharm NAD+ 1000 Pen in the UK
The Body Pharm NAD+ 1000 pen is available exclusively through JCSG.org for UK researchers. Use the buy box at the top of this page to order, or browse the full NAD+ research catalogue and the broader peptides available for research in the UK. Current pricing is confirmed on the live listing — add to cart now.
Sirtuin Activation and Mitochondrial Function: The Research Rationale
NAD+ is studied as a research target because it sits at the intersection of two distinct biochemical pathways: redox-coupled ATP synthesis in mitochondria and substrate-dependent deacetylation by the sirtuin family. Both pathways consume or depend on the oxidised coenzyme, and both decline measurably with age in mammalian tissue [3][4].
Mitochondrial oxidative phosphorylation
Within the electron transport chain, NAD+ is the oxidised acceptor that complex I reduces to NADH. This feeds electrons through complexes I–IV to drive proton pumping and downstream ATP synthesis. Gomes et al. (Cell, 2013) demonstrated in murine skeletal muscle that declining nuclear NAD+ disrupts nuclear–mitochondrial communication via a HIF-1α-mediated pseudohypoxic state, reducing expression of mitochondrially encoded oxidative phosphorylation subunits independently of PGC-1α [3]. NAD+ availability is therefore a rate-relevant variable in mitochondrial bioenergetics research, not merely a passive cofactor pool.
Sirtuin-dependent signalling
Sirtuins SIRT1 through SIRT7 are NAD+-dependent deacetylases (and, for some isoforms, mono-ADP-ribosyltransferases). They consume one molecule of NAD+ per deacetylation cycle, producing nicotinamide and 2'-O-acetyl-ADP-ribose. Guarente (Cell Metabolism, 2013) framed this stoichiometric NAD+ requirement as the mechanistic link between cellular energy status and downstream substrates including p53, FOXO transcription factors, PGC-1α, and histone H3K9/H4K16 [4]. Because sirtuin catalytic activity is sensitive to intracellular [NAD+]/[NADH] ratios in the low-micromolar range, even modest shifts in coenzyme availability can alter deacetylation kinetics on DNA repair, inflammatory, and metabolic substrates [4].
Frequently Asked Questions: Body Pharm NAD+ 1000 Pen
What does the Body Pharm NAD+ 1000 pen contain?
The Body Pharm NAD+ 1000 pen is vendor-described as containing 1000 mg of nicotinamide adenine dinucleotide (the oxidised coenzyme NAD+) in a pre-filled injection pen format intended for laboratory research use. Exact excipient composition, buffer system, and pH should be confirmed with the distributor. Request the batch-specific Certificate of Analysis at checkout on JCSG.org.
How many doses does the pen provide?
Dose count depends on the per-injection increment selected. With the Body Pharm NAD+ 1000 pen's vendor-stated 10/20/30 mg selectable increments, a 1000 mg pen can yield up to 100 discrete 10 mg aliquots — maximising the number of experimental conditions from a single consumable. Order now via JCSG.org to confirm current stock and specifications.
Is the NAD+ 1000 pen legal to buy in the UK?
NAD+ injection pens occupy an unlicensed-medicine grey area in the UK. No MHRA guidance, enforcement notice, or recall naming NAD+ or NAD+ injection pens has been issued between 2023 and 2026. General MHRA rules on unlicensed parenteral medicines, advertising restrictions, and borderline products still apply. Supply is restricted to bona fide research use only. JCSG.org sells the Body Pharm NAD+ 1000 pen as a research chemical for in vitro and laboratory investigation only.
How does subcutaneous NAD+ delivery differ from oral supplementation in research models?
Subcutaneous administration bypasses gastrointestinal hydrolysis and hepatic first-pass metabolism, both of which degrade orally administered NAD+ before systemic circulation. No 2023–2026 human RCT directly compares subcutaneous versus oral NAD+ pharmacokinetics. The mechanistic rationale rests on precursor (NR, NMN) trial data and foundational biology [3][4].
What storage conditions does the pen require?
Confirm Body Pharm-specific storage conditions with the distributor before use. Typical NAD+ injectable products are stored at 2–8 °C, protected from light, with 12–24 month unopened stability. Confirm conditions on the supplied label before use — and request the CoA at checkout on JCSG.org.
Where can I buy the Body Pharm NAD+ 1000 pen in the UK?
The Body Pharm NAD+ 1000 pen is available now on JCSG.org. Use the buy box at the top of this page, or go directly to your cart. For the full Body Pharm NAD+ range, visit the NAD+ research catalogue.
Related Peptides for Cellular Energy Research
Researchers studying NAD+ frequently work across an overlapping set of peptides examined in mitochondrial, metabolic, and tissue repair contexts. The four below are catalogued on the JCSG UK platform and appear most often in adjacent research literature. None of the descriptions below constitute therapeutic claims; all are framed as research compounds for in vitro and preclinical investigation.
MOTS-C
MOTS-C is a 16-amino-acid mitochondrial-derived peptide studied in metabolic signalling and exercise-mimetic pathways. Research interest centres on AMPK activation and insulin sensitivity in animal models. It sits within the same cellular energetics research category as NAD+ because both compounds target mitochondrial function and metabolic regulation.
BPC-157
BPC-157 is a pentadecapeptide fragment derived from a gastric protein, studied in preclinical tissue repair and angiogenesis models. Its inclusion in NAD+-adjacent procurement lists usually reflects multi-arm laboratory protocols rather than shared mechanism.
GHK-Cu
GHK-Cu is a copper-binding tripeptide studied in cellular repair contexts and gene expression modulation. Published transcriptomic work examines shifts across thousands of genes in cultured fibroblasts. It is frequently catalogued alongside longevity-adjacent compounds because both NAD+ and GHK-Cu target age-related cellular decline pathways.
Tesamorelin
Tesamorelin is a growth hormone-releasing hormone analogue studied in metabolic research, particularly visceral adipose tissue endpoints in clinical literature.
For the parent category and full procurement context, see the NAD+ overview and the broader catalogue of peptides available for research in the UK.
Order the Body Pharm NAD+ 1000 Pen on JCSG.org Today
JCSG.org is the UK's dedicated Body Pharm research peptide store. The Body Pharm NAD+ 1000 pen is in stock now — use the buy box at the top of this page to see the current price and add to cart.
- Precision dosing: 10/20/30 mg selectable increments for fine dose-response titration.
- High-capacity reservoir: 1000 mg total fill — up to 100 discrete aliquots at 10 mg.
- Research-grade quality: Body Pharm manufacture — request your batch CoA at checkout.
- Fast UK dispatch: Order now via the JCSG.org cart.
Before ordering, confirm in writing with the distributor: (1) batch-specific Certificate of Analysis; (2) exact storage conditions and unopened shelf life; (3) complete list of included accessories and single-use needle specifications; (4) vendor confirmation that the product is supplied for research use only and not for human administration. Cross-check your institution's ethics, COSHH, and controlled substances policies against the research-only designation.
Add the Body Pharm NAD+ 1000 Pen to your cart now — or browse all Body Pharm peptides at JCSG.org/uk/peptides/.
